瑞康醫藥(002589.SZ)與杭州奮華投資成立杭州仁華慧德吉祥天醫藥數碼科技
格隆匯12月4日丨瑞康醫藥(002589.SZ)公佈，公司於2019年12月4日召開第四屆董事會第二次會議審議通過了《關於與杭州奮華投資合夥企業(有限合夥)合資設立公司暨對外投資的議案》，同意公司與專業投資機構杭州奮華投資合夥企業(有限合夥)(“杭州奮華投資”)成立杭州仁華慧德吉祥天醫藥數碼科技有限公司(“杭州吉祥天”、“標的公司”)。
公司與杭州奮華投資本着誠實信用、公平互利、平等自願的原則，經友好協商，共同投資設立杭州吉祥天，公司出資規模為人民幣1.3億元，其中瑞康醫藥出資1.04億元，杭州奮華投資出資0.26億元。
杭州奮華投資成立於2018年05月02日，主營業務為實業投資、投資管理和投資諮詢服務等，認繳註冊資本為300.15億人民幣。杭州奮華投資是浙商創投股份有限公司旗下的股權投資基金合夥企業。主要投向包括港口開發、醫藥材料、家居、環保設備、環境處理、服裝、鋰電池原料、物聯網等領域。
合作目的：杭州吉祥天是瑞康醫藥集團與杭州奮華投資攜手打造的醫療健康服務平台，該平台將在瑞康醫藥傾力數年打造的醫藥供應鏈金融業務平台——瑞信的基礎上，融通杭州奮華投資、浙商創投股份有限公司互聯網技術資源和金融服務創新能力，共同打造一個醫藥上游供應商-醫藥流通企業-醫療機構-金融機構全覆蓋的醫藥業務數據整合平台，同時為醫療健康全產業鏈提供信息聯通和資金融通，打造行業生態新模式。
瑞康醫藥和杭州奮華投資合作，通過平台化的運營模式，實現信息直聯、信用傳導、牌照互補(醫藥牌照、金融牌照)的產融結合的一體化聯合體。基於我國醫藥商業的發展的基礎和條件，藉助我國大力扶持供應鏈金融的政策，發揮自身的優勢，將醫藥商業行業的業務場景應用到實際當中去，最終實現從重資本、低毛利的物流配送向輕資產、高附加值的消費、科技模式的轉型創新。
此次投資設立杭州吉祥天，有利於公司在未來業務重點佈局地區的業務拓展，與杭州奮華投資通力合作，對產業鏈進行前瞻性佈局，增強公司的核心競爭力和持續盈利能力。公司本次對外投資設立杭州吉祥天是基於整體的發展戰略基礎上進行的，符合公司的戰略佈局及發展需求，能夠充分發揮公司與專業投資機構的互補優勢，增強可持續發展能力。此次投資資金來源為公司自有資金，不會對公司財務及經營狀況產生不利影響，不存在損害公司及全體股東利益的情形。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
